NASDAQ:CELG - Celgene Stock Price, Price Target & More

$89.62 -1.39 (-1.53 %)
(As of 04/20/2018 06:18 AM ET)
Previous Close$91.01
Today's Range$89.27 - $91.80
52-Week Range$84.25 - $147.17
Volume3.94 million shs
Average Volume7.70 million shs
Market Capitalization$68.46 billion
P/E Ratio13.10
Dividend YieldN/A
Beta1.49

About Celgene (NASDAQ:CELG)

Celgene logoCelgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; and Prothena Corporation plc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Debt-to-Equity Ratio2.29%
Current Ratio4.99%
Quick Ratio4.80%

Price-To-Earnings

Trailing P/E Ratio13.10
Forward P/E Ratio11.65
P/E Growth0.61

Sales & Book Value

Annual Sales$13.00 billion
Price / Sales5.18
Cash Flow$7.5059 per share
Price / Cash11.94
Book Value$8.79 per share
Price / Book10.20

Profitability

EPS (Most Recent Fiscal Year)$6.84
Net Income$2.94 billion
Net Margins22.38%
Return on Equity67.50%
Return on Assets18.33%

Miscellaneous

Employees7,467
Outstanding Shares752,180,000

How to Become a New Pot Stock Millionaire

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its Board of Directors has approved a stock buyback program on Wednesday, February 14th 2018, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company's board believes its shares are undervalued.

How were Celgene's earnings last quarter?

Celgene (NASDAQ:CELG) announced its quarterly earnings results on Thursday, January, 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.78 by $0.09. The biopharmaceutical company had revenue of $3.48 billion for the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business's quarterly revenue was up 16.9% on a year-over-year basis. During the same period last year, the business earned $1.61 EPS. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Friday, May, 4th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided EPS guidance of $8.70-8.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.65. The company issued revenue guidance of $14.4-14.8 billion, compared to the consensus revenue estimate of $14.77 billion.

What price target have analysts set for CELG?

31 brokers have issued 12 month target prices for Celgene's shares. Their predictions range from $85.00 to $166.00. On average, they expect Celgene's share price to reach $126.4536 in the next twelve months. View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. According to Zacks Investment Research, "Celgene was on the look-out of new deals and acquisitions given a lacklustre 2017. The company recently acquired Juno Therapeutics and added JCAR017 (lisocabtagene maraleucel; liso-cel) to Celgene’s lymphoma pipeline.  JCAR017 is a best-in-class CD19-directed CAR-T candidate, currently in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma.  The candidate is expected to obtain regulatory approval in the United States in 2019 and generate sales of approximately $3 billion.  The bluebird deal will further bolster Celgene’s presence in the CAR-T space. Things have been on the downturn for the company since last October after a series of pipeline failures. A late stage study on its lead cancer drug Revlimid in combination with Rituxan failed. Celgene suffered yet another setback when it received Refusal to File letter from the FDA regarding its New Drug Application for multiple sclerosis candidate ozanimod." (4/19/2018)
  • 2. Cann analysts commented, "Celgene announced today that John Weiland has been elected to its board of directors. Mr. Weiland was most recently President and Chief Operating Officer of C.R. Bard, Inc. Prior to this role, Mr. Weiland held the position of Group President of Bard and had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide Manufacturing Operations. We believe Mr. Weiland will bring significant commercial and operational experience to the Celgene Board." (2/15/2018)
  • 3. Cantor Fitzgerald analysts commented, "CELG’s current CEO, Mark Alles, will assume the role of Chairman of the Board, following the retirement of current COB Robert Hugin, effective February 5th, which follows his departure as President in early 2016." (1/29/2018)

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 59)
  • Mr. Peter N. Kellogg BSE, MBA, Exec. VP, CFO & Chief Accounting Officer (Age 62)
  • Mr. Rupert J. Vessey, Exec. VP and Pres of Research & Early Devel. (Age 53)
  • Mr. Patrick E. Flanigan III, Corp. VP of Investor Relations
  • Mr. Gerald F. Masoudi, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50)

Has Celgene been receiving favorable news coverage?

Media headlines about CELG stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celgene earned a news sentiment score of 0.22 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $89.62.

How big of a company is Celgene?

Celgene has a market capitalization of $68.46 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (CELG)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  1,739 (Vote Outperform)
Underperform Votes:  548 (Vote Underperform)
Total Votes:  2,287
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celgene (NASDAQ:CELG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
31 Wall Street analysts have issued ratings and price targets for Celgene in the last 12 months. Their average twelve-month price target is $126.4536, suggesting that the stock has a possible upside of 41.10%. The high price target for CELG is $166.00 and the low price target for CELG is $85.00. There are currently 1 sell rating, 12 hold ratings, 17 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.582.582.552.68
Ratings Breakdown: 1 Sell Rating(s)
12 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $126.4536$127.3464$129.7750$149.3208
Price Target Upside: 41.10% upside44.27% upside27.58% upside23.07% upside

Celgene (NASDAQ:CELG) Consensus Price Target History

Price Target History for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Credit Suisse GroupSet Price TargetBuy$129.00LowView Rating Details
4/13/2018Morgan StanleyReiterated RatingEqual -> Equal Weight$93.00LowView Rating Details
4/2/2018Cantor FitzgeraldSet Price TargetHold$112.00LowView Rating Details
3/28/2018Leerink SwannSet Price TargetBuy$123.00HighView Rating Details
3/26/2018Goldman SachsLower Price TargetSell -> Sell$97.00 -> $85.00LowView Rating Details
3/21/2018JPMorgan ChaseInitiated CoverageOverweight -> Overweight$110.00LowView Rating Details
3/1/2018Robert W. BairdReiterated RatingHold$92.00MediumView Rating Details
2/28/2018BMO Capital MarketsLower Price TargetOutperform -> Outperform$144.00 -> $139.00HighView Rating Details
2/28/2018William BlairReiterated RatingBuyHighView Rating Details
2/28/2018UBSSet Price TargetBuy$106.00HighView Rating Details
2/28/2018Stifel NicolausReiterated RatingBuy -> Buy$130.00 -> $128.00HighView Rating Details
2/28/2018SunTrust BanksDowngradeBuy -> Hold$139.00 -> $106.00HighView Rating Details
2/15/2018CannReiterated RatingBuy$163.00LowView Rating Details
2/13/2018BarclaysUpgradeEqual Weight -> Overweight$91.51 -> $105.00LowView Rating Details
2/4/2018MizuhoReiterated RatingBuy$128.00HighView Rating Details
1/23/2018Royal Bank of CanadaReiterated RatingTop PickLowView Rating Details
1/23/2018BTIG ResearchReiterated RatingHoldMediumView Rating Details
1/18/2018Piper JaffrayReiterated RatingHold$104.00LowView Rating Details
1/10/2018GuggenheimReiterated RatingBuy$147.00LowView Rating Details
1/8/2018Deutsche BankSet Price TargetHold$110.00LowView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$166.00HighView Rating Details
1/5/2018Bank of AmericaDowngradeBuy -> Neutral$104.68 -> $120.00MediumView Rating Details
12/27/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$121.00HighView Rating Details
12/22/2017CitigroupReiterated RatingHoldMediumView Rating Details
12/8/2017Atlantic SecuritiesUpgradeNeutral -> OverweightHighView Rating Details
11/16/2017Canaccord GenuitySet Price TargetBuy$140.00N/AView Rating Details
10/27/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
10/26/2017Wells FargoDowngradeOutperform -> Market PerformN/AView Rating Details
10/16/2017Jefferies GroupReiterated RatingBuy$160.00N/AView Rating Details
9/12/2017CowenReiterated RatingBuy$150.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
4/28/2016Raymond JamesReiterated RatingBuyN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Celgene (NASDAQ:CELG) Earnings History and Estimates Chart

Earnings by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Earnings Estimates

2018 EPS Consensus Estimate: $7.73
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.77$1.77$1.77
Q2 20181$1.88$1.88$1.88
Q3 20181$2.00$2.00$2.00
Q4 20182$2.08$2.08$2.08

Celgene (NASDAQ CELG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2018$1.78N/AView Earnings Details
4/25/2018$1.96N/AView Earnings Details
1/25/2018Q4 2017$1.78$1.87$3.4645 billion$3.4830 billionViewListenView Earnings Details
10/26/2017Q3 2017$1.87$1.91$3.4167 billion$3.2870 billionViewN/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.2324 billion$3.2680 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.0367 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.9830 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
10/28/2010Q3 2010$0.32$0.32ViewN/AView Earnings Details
7/29/2010Q2 2010$0.30$0.30ViewN/AView Earnings Details
4/29/2010Q1 2010$0.28$0.27ViewN/AView Earnings Details
1/28/2010Q4 2009$0.29$0.29ViewN/AView Earnings Details
10/22/2009Q3 2009$0.25$0.25ViewN/AView Earnings Details
7/23/2009Q2 2009$0.21$0.20ViewN/AView Earnings Details
4/30/2009Q1 2009$0.20$0.16ViewN/AView Earnings Details
1/29/2009Q4 2008$0.19$0.19ViewN/AView Earnings Details
10/23/2008Q3 2008$0.18$0.17ViewN/AView Earnings Details
7/24/2008Q2 2008$0.16$0.15ViewN/AView Earnings Details
5/8/2008Q1 2008$0.16$0.17ViewN/AView Earnings Details
1/31/2008Q4 2007$0.15$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Celgene (NASDAQ:CELG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Celgene (NASDAQ CELG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 78.53%
Insider Trading History for Celgene (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2018James J LoughlinDirectorSell9,250$92.01$851,092.50View SEC Filing  
2/23/2018Ernest MarioDirectorSell13,370$94.49$1,263,331.30View SEC Filing  
2/20/2018Gilla KaplanDirectorSell9,250$94.83$877,177.5094,801View SEC Filing  
2/15/2018Gilla KaplanDirectorSell9,250$95.99$887,907.5094,801View SEC Filing  
2/8/2018Mark J AllesInsiderBuy3,260$91.90$299,594.00178,904View SEC Filing  
9/25/2017Terrie CurranInsiderSell1,727$143.89$248,498.033,925View SEC Filing  
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.0085,551View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.509,250View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.1269,424View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.0076,301View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.0032,877View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.005,000View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.801,033,909View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.509,250View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.304,004View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.0032,169View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.3973,109View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00778View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.0018,600View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.5650,000View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.0031,332View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.4072,142View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.0042,919View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.001,022,201View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.001,122,201View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.2872,518View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.0019,785View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.0082,449View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.6888,485View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.0088,485View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.1625,705View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00100,671View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.7850View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.0022,688View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.7815,349View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celgene (NASDAQ CELG) News Headlines

Source:
DateHeadline
Zacks Investment Research Upgrades Celgene (CELG) to "Hold"Zacks Investment Research Upgrades Celgene (CELG) to "Hold"
www.americanbankingnews.com - April 19 at 11:46 AM
BRIEF-Celgene Announces Changes To Its Board Of DirectorsBRIEF-Celgene Announces Changes To Its Board Of Directors
www.reuters.com - April 19 at 10:30 AM
Celgene (CELG) Announces Board ChangesCelgene (CELG) Announces Board Changes
www.streetinsider.com - April 19 at 10:30 AM
Leerink Swann Analysts Raise Earnings Estimates for Celgene (CELG)Leerink Swann Analysts Raise Earnings Estimates for Celgene (CELG)
www.americanbankingnews.com - April 19 at 7:04 AM
Celgene (CELG) PT Set at $129.00 by Credit Suisse GroupCelgene (CELG) PT Set at $129.00 by Credit Suisse Group
www.americanbankingnews.com - April 18 at 8:41 AM
Q1 2018 EPS Estimates for Celgene (CELG) Boosted by Leerink SwannQ1 2018 EPS Estimates for Celgene (CELG) Boosted by Leerink Swann
www.americanbankingnews.com - April 18 at 7:58 AM
Celgene (CELG) Scheduled to Post Earnings on WednesdayCelgene (CELG) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 18 at 1:52 AM
Celgene (CELG) Stock Rating Upgraded by Zacks Investment ResearchCelgene (CELG) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 17 at 5:54 PM
Risankizumab Could Be AbbVie’s Long-Term Growth DriverRisankizumab Could Be AbbVie’s Long-Term Growth Driver
finance.yahoo.com - April 17 at 10:33 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action ...SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action ...
globenewswire.com - April 16 at 3:51 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELGSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG
finance.yahoo.com - April 16 at 3:51 PM
Celgene (CELG) PT Set at $134.00 by MizuhoCelgene (CELG) PT Set at $134.00 by Mizuho
www.americanbankingnews.com - April 15 at 8:22 PM
Celgene (CELG) Upgraded to "Buy" by ArgusCelgene (CELG) Upgraded to "Buy" by Argus
www.americanbankingnews.com - April 15 at 9:23 AM
CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100000 ...CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100000 ...
globenewswire.com - April 14 at 5:55 PM
CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELGCELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG
finance.yahoo.com - April 14 at 5:55 PM
Morgan Stanley Resumes Celgene (CELG) at EqualweightMorgan Stanley Resumes Celgene (CELG) at Equalweight
www.streetinsider.com - April 13 at 3:46 PM
Morgan Stanley Reiterates Equal Weight Rating for Celgene (CELG)Morgan Stanley Reiterates Equal Weight Rating for Celgene (CELG)
www.americanbankingnews.com - April 13 at 11:01 AM
 Analysts Expect Celgene Co. (CELG) Will Announce Quarterly Sales of $3.50 Billion Analysts Expect Celgene Co. (CELG) Will Announce Quarterly Sales of $3.50 Billion
www.americanbankingnews.com - April 13 at 4:41 AM
Otezla: Shoring Up Celgene’s Top LineOtezla: Shoring Up Celgene’s Top Line
finance.yahoo.com - April 12 at 3:49 PM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene CorporationThe Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene Corporation
finance.yahoo.com - April 12 at 3:49 PM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead ...INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead ...
www.businesswire.com - April 12 at 11:24 AM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - April 12 at 11:23 AM
Celgene (CELG) Stock Rating Lowered by ValuEngineCelgene (CELG) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 12 at 10:53 AM
Celgene (CELG) Earns "Outperform" Rating from OppenheimerCelgene (CELG) Earns "Outperform" Rating from Oppenheimer
www.americanbankingnews.com - April 11 at 10:42 PM
Novartis Enters Agreement to Acquire AveXisNovartis Enters Agreement to Acquire AveXis
finance.yahoo.com - April 11 at 3:45 PM
Zacks: Analysts Expect Celgene Co. (CELG) Will Post Earnings of $2.01 Per ShareZacks: Analysts Expect Celgene Co. (CELG) Will Post Earnings of $2.01 Per Share
www.americanbankingnews.com - April 11 at 3:14 AM
Celgene Stock Performance in 1Q18Celgene Stock Performance in 1Q18
finance.yahoo.com - April 10 at 3:43 PM
Agios Pharmaceuticals Shares Rise on Buyout SpeculationAgios Pharmaceuticals Shares Rise on Buyout Speculation
finance.yahoo.com - April 10 at 3:43 PM
Celgene (CELG) Raised to Strong-Buy at VetrCelgene (CELG) Raised to Strong-Buy at Vetr
www.americanbankingnews.com - April 10 at 9:44 AM
Celgene (CELG) Lowered to Buy at VetrCelgene (CELG) Lowered to Buy at Vetr
www.americanbankingnews.com - April 9 at 8:36 PM
Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018
www.businesswire.com - April 9 at 10:45 AM
Celgene hunts deals to offset loss of Revlimid patent protectionCelgene hunts deals to offset loss of Revlimid patent protection
www.ft.com - April 8 at 3:48 PM
Hagens Berman Alerts Investors in Celgene Corporation to the May 29, 2018 Lead Plaintiff Deadline in the Pending ...Hagens Berman Alerts Investors in Celgene Corporation to the May 29, 2018 Lead Plaintiff Deadline in the Pending ...
globenewswire.com - April 7 at 5:10 PM
Celgene (CELG) PT Set at $162.00 by Cantor FitzgeraldCelgene (CELG) PT Set at $162.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 7 at 11:47 AM
Sanford C. Bernstein Initiates Coverage on Celgene (CELG)Sanford C. Bernstein Initiates Coverage on Celgene (CELG)
www.americanbankingnews.com - April 6 at 10:54 PM
JPMorgan Chase Reiterates Buy Rating for Celgene (CELG)JPMorgan Chase Reiterates Buy Rating for Celgene (CELG)
www.americanbankingnews.com - April 6 at 10:22 PM
Celgene (CELG) Upgraded at VetrCelgene (CELG) Upgraded at Vetr
www.americanbankingnews.com - April 6 at 12:43 PM
Celgene (CELG) Price Target Cut to $115.00Celgene (CELG) Price Target Cut to $115.00
www.americanbankingnews.com - April 6 at 12:23 PM
CELG INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Celgene Corporation ...CELG INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Celgene Corporation ...
www.businesswire.com - April 6 at 11:07 AM
FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein ...FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein ...
www.businesswire.com - April 5 at 3:45 PM
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Celgene Corporation Investors (CELG)Glancy Prongay & Murray LLP Continues Investigation on Behalf of Celgene Corporation Investors (CELG)
www.businesswire.com - April 5 at 3:45 PM
Long-Term Celgene (CELG) Investors: Johnson Fistel Investigates Celgene Corporation; Encourages Long-Term Investors to Contact the FirmLong-Term Celgene (CELG) Investors: Johnson Fistel Investigates Celgene Corporation; Encourages Long-Term Investors to Contact the Firm
www.prnewswire.com - April 5 at 2:16 PM
CELG INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Celgene Corporation ...CELG INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Celgene Corporation ...
www.businesswire.com - April 5 at 8:20 AM
Celgene (CELG): COO Departure An Incremental Positive - Cantor FitzgeraldCelgene (CELG): COO Departure An Incremental Positive - Cantor Fitzgerald
www.streetinsider.com - April 4 at 5:37 PM
CELG INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Celgene Corporation InvestorsCELG INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Celgene Corporation Investors
finance.yahoo.com - April 4 at 5:37 PM
Celgene (CELG) Given Hold Rating at Cantor FitzgeraldCelgene (CELG) Given Hold Rating at Cantor Fitzgerald
www.americanbankingnews.com - April 4 at 4:10 PM
Oppenheimer Reaffirms Buy Rating for Celgene (CELG)Oppenheimer Reaffirms Buy Rating for Celgene (CELG)
www.americanbankingnews.com - April 4 at 12:34 AM
Celgene (CELG) President and COO to Step Down: Whats Ahead?Celgene (CELG) President and COO to Step Down: What's Ahead?
finance.yahoo.com - April 3 at 3:44 PM
Celgene (CELG) President and COO to Step Down: What's Ahead?Celgene (CELG) President and COO to Step Down: What's Ahead?
finance.yahoo.com - April 3 at 3:44 PM
Celgene underperforms after COO exitCelgene underperforms after COO exit
seekingalpha.com - April 3 at 2:13 PM

SEC Filings

Celgene (NASDAQ:CELG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celgene (NASDAQ:CELG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celgene (NASDAQ CELG) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.